Texas Yale Capital Corp. lessened its stake in shares of DENTSPLY SIRONA Inc (NASDAQ:XRAY) by 50.0% in the second quarter, according to the company in its most recent filing with the SEC. The fund owned 15,625 shares of the medical instruments supplier’s stock after selling 15,625 shares during the quarter. Texas Yale Capital Corp.’s holdings in DENTSPLY SIRONA were worth $912,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently bought and sold shares of the company. Hanseatic Management Services Inc. acquired a new stake in DENTSPLY SIRONA in the 1st quarter worth about $30,000. Cornerstone Advisors Inc. raised its stake in DENTSPLY SIRONA by 62.0% in the 2nd quarter. Cornerstone Advisors Inc. now owns 904 shares of the medical instruments supplier’s stock worth $53,000 after purchasing an additional 346 shares in the last quarter. Arcadia Investment Management Corp MI acquired a new stake in DENTSPLY SIRONA in the 2nd quarter worth about $58,000. Private Capital Group LLC raised its stake in DENTSPLY SIRONA by 74.7% in the 1st quarter. Private Capital Group LLC now owns 1,223 shares of the medical instruments supplier’s stock worth $61,000 after purchasing an additional 523 shares in the last quarter. Finally, Quadrant Capital Group LLC raised its stake in DENTSPLY SIRONA by 1,047.2% in the 1st quarter. Quadrant Capital Group LLC now owns 1,411 shares of the medical instruments supplier’s stock worth $68,000 after purchasing an additional 1,288 shares in the last quarter. Institutional investors own 91.86% of the company’s stock.
XRAY has been the subject of several analyst reports. Wellington Shields upgraded shares of DENTSPLY SIRONA from a “hold” rating to a “gradually accumulate” rating in a research note on Friday, August 2nd. Barrington Research reiterated a “buy” rating and issued a $63.00 price objective on shares of DENTSPLY SIRONA in a research note on Monday. HC Wainwright reiterated a “neutral” rating and issued a $57.00 price objective (up previously from $55.00) on shares of DENTSPLY SIRONA in a research note on Tuesday, July 9th. Wolfe Research initiated coverage on shares of DENTSPLY SIRONA in a research note on Thursday, May 30th. They issued a “peer perform” rating for the company. Finally, Evercore ISI initiated coverage on shares of DENTSPLY SIRONA in a research note on Friday, July 26th. They issued an “in-line” rating for the company. One analyst has rated the stock with a sell rating, ten have issued a hold rating and six have given a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $53.77.
DENTSPLY SIRONA (NASDAQ:XRAY) last released its earnings results on Friday, August 2nd. The medical instruments supplier reported $0.66 EPS for the quarter, beating the consensus estimate of $0.62 by $0.04. The firm had revenue of $1.01 billion for the quarter, compared to analyst estimates of $1.04 billion. DENTSPLY SIRONA had a net margin of 2.67% and a return on equity of 9.19%. The business’s quarterly revenue was down 3.1% compared to the same quarter last year. During the same period last year, the firm earned $0.60 EPS. As a group, analysts anticipate that DENTSPLY SIRONA Inc will post 2.38 earnings per share for the current year.
The business also recently declared a quarterly dividend, which was paid on Friday, July 12th. Investors of record on Friday, June 28th were issued a dividend of $0.0875 per share. The ex-dividend date of this dividend was Thursday, June 27th. This is a positive change from DENTSPLY SIRONA’s previous quarterly dividend of $0.09. This represents a $0.35 annualized dividend and a dividend yield of 0.69%. DENTSPLY SIRONA’s payout ratio is 17.41%.
In related news, CEO Donald M. Jr. Casey purchased 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 29th. The shares were bought at an average cost of $53.68 per share, with a total value of $536,800.00. Following the acquisition, the chief executive officer now owns 105,631 shares of the company’s stock, valued at approximately $5,670,272.08. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Betsy D. Holden purchased 2,720 shares of the firm’s stock in a transaction that occurred on Thursday, June 6th. The shares were bought at an average cost of $55.31 per share, for a total transaction of $150,443.20. Following the completion of the acquisition, the director now directly owns 9,224 shares in the company, valued at approximately $510,179.44. The disclosure for this purchase can be found here. Over the last ninety days, insiders have purchased 22,720 shares of company stock worth $1,223,243 and have sold 104,462 shares worth $5,755,004. Insiders own 0.62% of the company’s stock.
DENTSPLY SIRONA Profile
DENTSPLY SIRONA Inc designs, develops, manufactures, and markets various dental and oral health products, and other consumable healthcare products primarily for the professional dental market worldwide. The company operates in two segments, Technologies & Equipment; and Consumables. Its dental supplies include endodontic instruments and materials, dental anesthetics, prophylaxis pastes, dental sealants, impression materials, restorative materials, tooth whiteners, and topical fluoride products; and small equipment products comprise dental hand pieces, intraoral curing light systems, dental diagnostic systems, and ultrasonic scalers and polishers.
Further Reading: Does a trade war provide a risk to the global economy?
Receive News & Ratings for DENTSPLY SIRONA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA and related companies with MarketBeat.com's FREE daily email newsletter.